Remarkably, these alterations are fully reversed within hours of acute treatment with the ATP-competitive mTORC1/2 kinase inhibitor AZD8055, demonstrating the direct and dynamic role of mTOR in mediating the tumor-induced alterations to peritumoral neurons [11,113] (Figure 2). This evidence concerns the gene MTOR and neoplasm.